| pubmed-article:17690600 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17690600 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:17690600 | lifeskim:mentions | umls-concept:C0003289 | lld:lifeskim |
| pubmed-article:17690600 | lifeskim:mentions | umls-concept:C0011570 | lld:lifeskim |
| pubmed-article:17690600 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:17690600 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:17690600 | pubmed:dateCreated | 2007-8-10 | lld:pubmed |
| pubmed-article:17690600 | pubmed:abstractText | Sparse data exist regarding the risks and benefits of treating bipolar-II depression with antidepressants alone. On the basis of studies of bipolar-I patients, treatment guidelines suggest antidepressants should be augmented with mood stabilizers. Whether these recommendations apply to bipolar-II is unclear. A post-hoc analysis of a double-blind study, which compared the relative efficacy of placebo, imipramine and phenelzine in depressed outpatients. Patients rated 1 ('very much improved') or 2 ('much improved') on the Clinical Global Inventory Scale were considered responders. In an intent to treat analysis, no significant differences between bipolar patients (N=62) and unipolar patients (N=248) in response rates to placebo, imipramine and phenelzine were seen. No patient developed manic symptoms that required medication discontinuation or mood stabilizer augmentation. Antidepressant monotherapy was found to be a safe and effective treatment for bipolar-II depression. | lld:pubmed |
| pubmed-article:17690600 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17690600 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17690600 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17690600 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17690600 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17690600 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17690600 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17690600 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17690600 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17690600 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:17690600 | pubmed:issn | 0268-1315 | lld:pubmed |
| pubmed-article:17690600 | pubmed:author | pubmed-author:StewartJonath... | lld:pubmed |
| pubmed-article:17690600 | pubmed:author | pubmed-author:AgostiVitoV | lld:pubmed |
| pubmed-article:17690600 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17690600 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:17690600 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17690600 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17690600 | pubmed:pagination | 309-11 | lld:pubmed |
| pubmed-article:17690600 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:17690600 | pubmed:meshHeading | pubmed-meshheading:17690600... | lld:pubmed |
| pubmed-article:17690600 | pubmed:meshHeading | pubmed-meshheading:17690600... | lld:pubmed |
| pubmed-article:17690600 | pubmed:meshHeading | pubmed-meshheading:17690600... | lld:pubmed |
| pubmed-article:17690600 | pubmed:meshHeading | pubmed-meshheading:17690600... | lld:pubmed |
| pubmed-article:17690600 | pubmed:meshHeading | pubmed-meshheading:17690600... | lld:pubmed |
| pubmed-article:17690600 | pubmed:meshHeading | pubmed-meshheading:17690600... | lld:pubmed |
| pubmed-article:17690600 | pubmed:meshHeading | pubmed-meshheading:17690600... | lld:pubmed |
| pubmed-article:17690600 | pubmed:meshHeading | pubmed-meshheading:17690600... | lld:pubmed |
| pubmed-article:17690600 | pubmed:meshHeading | pubmed-meshheading:17690600... | lld:pubmed |
| pubmed-article:17690600 | pubmed:meshHeading | pubmed-meshheading:17690600... | lld:pubmed |
| pubmed-article:17690600 | pubmed:meshHeading | pubmed-meshheading:17690600... | lld:pubmed |
| pubmed-article:17690600 | pubmed:meshHeading | pubmed-meshheading:17690600... | lld:pubmed |
| pubmed-article:17690600 | pubmed:meshHeading | pubmed-meshheading:17690600... | lld:pubmed |
| pubmed-article:17690600 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17690600 | pubmed:articleTitle | Efficacy and safety of antidepressant monotherapy in the treatment of bipolar-II depression. | lld:pubmed |
| pubmed-article:17690600 | pubmed:affiliation | New York State Psychiatric Institute and Columbia College of Physicians and Surgeons, 1051 Riverside Drive, New York, NY 10032, USA. agostiv@pi.cpmc.columbia.edu | lld:pubmed |
| pubmed-article:17690600 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17690600 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:17690600 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
